drugset / Trial / NCT05917587

Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes

NCT05917587

Phase 0 Recruiting 30 enrolled Anna Stanhewicz, PhD
RandomizedParallel-groupTriple-blindBasic science

Summary

The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.

Timeline

Start
2024-09-11
Primary completion
2027-12-31
Completion
2028-06-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule 850 mg

Indications